Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.43%||178.00||0.7%||$1154.07m|
|LLY||Eli Lilly & Co.||-0.92%||367.00||1.1%||$1126.70m|
|MRK||Merck & Co., Inc.||-0.71%||109.05||0.7%||$1025.89m|
|BMY||Bristol-Myers Squibb Co.||-0.98%||80.08||1.1%||$764.15m|
|HZNP||Horizon Therapeutics Plc||2.10%||103.00||5.4%||$315.71m|
|IDXX||IDEXX Laboratories, Inc.||-1.92%||430.74||3.9%||$225.57m|
|NVO||Novo Nordisk A/S||-0.74%||125.19||0.1%||$171.53m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.00%||220.25||8.0%||$161.43m|
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.